Derisking Drug Discovery

We view disease modeling 
as a competitive game changer in future drug development. iPSCs combined with the latest gene editing technologies can build highly relevant disease models that directly reflect human disease
 at a patient-specific level.
 The use of such models is likely 
to positively impact attrition during Phase II efficacy studies. Our strategy for competitiveness, therefore, expands well beyond libraries and Medchem. Combined with our high-end target free discovery platform and medicinal chemistry capacities, our approach is worldwide unique.